OptimizeRx Corp (OPRX): auditor change — OptimizeRx dismisses UHY as auditor, appoints Grant Thornton effective March 2026

OptimizeRx Corp

Audit Committee dismissed UHY on March 25, 2026; Grant Thornton appointed March 26, 2026 for FY2026.
No disagreements or reportable events with UHY, except a previously disclosed material weakness in internal controls.
Material weakness related to third-party data completeness/accuracy; did not cause restatement or disagreements.
UHY provided letter agreeing with statements; filed as Exhibit 16.1.

item 4.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

OptimizeRx Corp engaged Grant Thornton LLP as its auditor.

Action: engagement
Auditor: Grant Thornton LLP

Exact text from the filing

On March 26, 2026, the Company and the Audit Committee engaged Grant Thornton LLP (“Grant Thornton”) to serve as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, effective immediately.

View on SEC.gov

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

OptimizeRx Corp dismissed UHY LLP as its auditor.

Action: dismissal
Auditor: UHY LLP

Exact text from the filing

On March 24, 2026, the Audit Committee (the “Audit Committee”) of the Board of Directors of OptimizeRx Corporation (the “Company”) approved the dismissal of, and on March 25, 2026 subsequently dismissed, UHY LLP (“UHY”) as the Company’s independent registered public accounting firm, effective immediately.

View on SEC.gov

Browse all auditor changes →

OptimizeRx Corp filing history →

Source: SEC EDGAR

accession 0001448431-26-000007

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.